Superior Planning, LLC’s Protagonist Therapeutics PTGX Stock Holding History

Superior Planning, LLC’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$29.2K	Buy	+207	New	+$29.5K	0.01%	548

Other funds holding PTGX

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Superior Planning, LLC's PTGX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 207 shares worth $29.2K. The stake represents 0.01% of the portfolio and ranks #548 among its holdings.

236 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Superior Planning, LLC held 207 shares of Protagonist Therapeutics worth $29.2K as of Q3 2026.
Protagonist Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Protagonist Therapeutics made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #548 holding.
236 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.